Vylor

IThe business

Vylor sells seed to farmers, and it licenses its seed technology to other seed companies. Corn is about 71% of sales, soybeans 19%.¹⁰ The flagship brand is Pioneer, which the company calls the number one corn and soybean brand in the US by share.² It operates in more than 70 countries, 80% of sales are in the Americas, and it has about 12,300 employees.² Its headquarters are in Johnston, Iowa.⁴

I want to say plainly what this page can and can’t be. Vylor has traded since 1 October 2026. Twenty-five closes, from $68.26 to $71.25, are the whole market record.¹ It has filed no annual report and no quarterly report as its own company. It will release its first results, for the third quarter, on 11 November.¹¹ What I do have is the Form 10 information statement of 24 September, which contains audited carve-out accounts for the Seed Business for 2023, 2024 and 2025, a half-year to 30 June 2026, and pro forma figures.² Every number labelled carve-out below comes from those accounts. They show how the seed business did as part of Corteva, with costs that Corteva allocated by sales. They are not what a free-standing Vylor would have reported.

How the spin-off worked

Each Corteva holder got one Vylor share for each Corteva share held on 24 September, and Vylor began trading on the NYSE on 1 October.⁴² There are about 667.2M shares, so $71.25 is a market value of $47.5B C (calculated).²¹ The legal form was that Vylor was spun out of Corteva. The accounting runs the other way. Because Vylor is the larger part, it is treated as the successor, so Corteva’s whole history, seed and crop protection together, becomes Vylor’s on paper, and the crop protection business is shown as a discontinued operation.² The filings therefore carry three versions of the same company: the carve-out (seed only, as Corteva ran it), the pro forma (seed only, adjusted for the new agreements and debt), and Corteva’s consolidated figures. I label which I am using each time.

The other half, now called New Corteva, kept crop protection and trades at $12.26.¹² On the same share count that is about $8.2B against Vylor’s $47.5B, so the market gives Vylor roughly 85% of the combined value C (calculated).¹²¹ Vylor also paid for the privilege. It borrowed so that about $3.5B of cash could go to New Corteva before the distribution, and it ended up with about $5.7B of debt against $1.1B of cash on the day.²

How it makes money

Three streams, in order of size.

Branded seed. A farmer plants a new crop every year, so seed is a repeat purchase. Vylor sells corn and soybean seed mainly through its own agents, who visit farms before planting and again at harvest, and through retail partners under the Brevant brand.² In 2025 sales grew 4%: prices and mix added 3 points and volume 2, and currency took 1 back.² In the first half of 2026 sales grew 4% again to $7,555M, with price and mix again +3 points and volume flat.² Over the last decade, management says, price and mix has added 2% to 3% a year.³

Traits, which are the genes that protect a crop. The best known is Enlist E3, a soybean trait for weed control. The company says it is planted on about 65% of US soybean acres, and that in Brazil it expects double-digit penetration in 2026, from under 5% before, with more than 30% at peak.²³ A trait is paid for inside the price of the seed when Vylor sells it, and it is paid for as a royalty when another seed company sells it. That is the third stream.

Licensing and royalties. This is the line that most changes the story. For years Vylor paid more for other firms’ traits than it earned from its own. The Form 10 says gross out-licensing income was $317M in 2025 and calls $439M the “net royalty cost”.² At the Investor Day, management said the net cost in 2025 was about $120M, and that in 2020 it was about $700M.³ The two statements agree if $439M is the gross royalty bill, because $439M less $317M is $122M. That is my reading, and I use $122M as the net. The aim is a net of zero in 2026, about +$300M in 2030 and about +$1B in 2035, and gross licensing income above $500M in 2027.³² There are more than 120 licensees, and the company says demand from independent seed firms exceeds its supply.³ One caution on the numbers: gross licensing income of “over a billion” by 2035 and a net of about $1B in the same year can both be true only if almost no royalty expense is left by then. I can’t tell from the documents whether that is what is meant.³

Two smaller items sit beside these. In January 2026 Vylor and Bayer settled an agrobacterium cross-license dispute, and Corteva dropped its AAD-1 patent claims. The settlement cost $610M, of which $546M was paid by mid-year, and it is booked in 2025.² Management says it now has freedom to operate in corn.³ And Vylor must buy its seed treatments from New Corteva under an exclusive supply agreement, priced at arm’s length, and it licenses patents from New Corteva inside its own fields.² It is not fully independent of its former parent.

What it costs to do it

In 2025, on the carve-out basis, cost of goods was 48% of sales, down from 54% in 2023. Research was 10%, and selling and administration 21%.² Cost of goods fell $233M in 2025 from commodity costs ($190M), productivity ($125M) and lower royalty expense ($50M), less higher volume and an accrual.² Operating EBITDA was $2,423M, a 24.5% margin. Management expects R&D to run near 10% of sales, about $1B a year.²³ Capital spending was $346M in 2025 and is planned near $400M in 2026.²

The growth platforms

Management names four. Each is early.

• Gene editing. The lead product is multi-disease-resistant corn, which packs resistance to four diseases into one place in the genome. The company says it has USDA clearance and targets a US launch in 2028.² It claims the second largest gene-editing patent estate after China.² I can’t verify that count.
• Hybrid wheat. A first hard red winter wheat hybrid in North America as early as 2027; internal trials show a yield gain of 10% to 20%; management sees about $1B of revenue by the end of the next decade.²³
• Biofuel feedstocks. A 50:50 venture with BP, called Etlas, launched on 7 January 2026 to grow winter crops for fuel, with first supply in 2027; and a winter canola programme with Bunge and Chevron.²
• Short-stature corn and triple-stack licensing late in the decade, with the triple stack open to licensing from 2027 and about $40M of extra licensing income by 2029.²³

All of this is on top of the core. If I had to give a one-line view of the business, it is a very good corn and soybean seed franchise, bought and sold on the weather, with a new licensing business that is large in ambition and small in today’s results.

What Vylor is not

It does not make crop protection chemicals. New Corteva does, and the two are now separate companies. Before 1 October, Corteva could offer a farmer both the seed and the chemicals that go on it. Management argued the split lets each pursue its own priorities, but a seed company without its own chemistry may lose a little of the farm-level bundle, and I can’t measure that.²

IIThe moat

What keeps a rival from copying the profit? In seed the possible sources are genes, brand, distribution, and legal protection. Here is each, and how well I can test it.

Genes and the data behind them

Vylor says it has the largest germplasm pool in the world, across more than ten crops, and adds 200 to 300 new hybrids and varieties a year.² Bayer says it launches 400 to 500 a year, so the count is not the point. What matters is whether new hybrids beat the old ones.⁵ Management states that annual genetic gain has been about 1% to 2% and believes gene editing could double it.² A world-record corn yield of 623.84 bushels an acre in 2023 was set with a Pioneer hybrid, and Pioneer soybeans beat all competitors by an average 3.5 bushels in the 2024 comparison it cites.² Those are the company’s tests, chosen by the company. Still, the proof that matters shows up in price. If farmers did not see the yield, price and mix would not add 3% a year in a flat-volume market.

The brand and the sales force

Pioneer is sold mainly through agents who visit the farm, which the company calls a unique route to market. It is also a costly one: selling and administration was 21% of sales in 2025.² Enlist E3 is in more than 95% of Vylor’s own soybean seed, and licensing puts it into more than 100 other seed brands.³ One management claim I find convincing: over 2015 to 2025, the company says, a leading hybrid gave farmers more than $300 of added value per bag while the price of the bag rose about $100, so growers kept roughly two thirds of what they gained.³ A seller who leaves most of the gain with the buyer is not likely to be undercut easily. A seller who keeps one third can raise price only as fast as yield rises.

Legal protection

The company owns about 5,300 US patents and about 2,500 abroad, and has about 2,000 applications pending.² But the years left are short for a good part of them. About 1,000 US patents expire within five years, and 1,800 more in six to ten years. The ones that matter most are named: patents for the Enlist corn and soybean traits expire from 2031 to 2032, and Qrome, a corn insect-protection trait, in 2032. The next generation of corn and soy traits is covered into the 2040s.² Enlist E3 is the 65% of US soybean acres that makes the licensing story, so the 2035 aim has to be reached through a patent expiry that falls on the way.

What the numbers say

The test is whether the profit is kept. The best long record is Corteva’s own Seed segment. Its segment margin went from 14.5% in 2018 and 13.7% in 2019 to 26.6% in 2025, with sales up 26% over the same stretch C (calculated).¹³¹⁰ On the carve-out basis, segment EBITDA margins in the Americas rose from 29.5% in 2023 to 35.7% in 2025, and in the rest of the world from 26.7% to 29.8% C (calculated).² Part of that came from falling commodity costs and part from lower net royalties. I can’t say how much was lasting advantage and how much was a good stretch for the farm economy. The 2025 jump in operating EBITDA, 16%, came with volume up 2% and price and mix up 3%, which looks like lasting advantage, and with $190M of lower commodity costs, which is not.

My view

The protection is wide in North American corn, where genes, brand and a direct sales force all reinforce each other and the record shows pricing power. It is thinner in soybean traits, where Bayer says plainly that it expects to regain trait leadership in North America by 2032, which implies Vylor holds it today.⁵ And it is new in licensing, where Vylor is moving from buyer to seller of technology, and rivals who were its landlords are now its competitors. I would rate each one differently, so I do not put a single number on it.

IIIThe competitive advantage

Protection keeps the profit. The advantage is why Vylor earns more than the rest in the first place. Five things I can test.

Size in a business that has fixed costs

Vylor spends about $1B a year on research, and the Form 10 says it expects R&D at about 10% of sales.²³ A smaller rival has to spread a bill of that kind over fewer acres. Syngenta’s whole seeds unit sold $4.8B in 2025 and BASF’s Seeds & Traits EUR 2.0B.¹⁶¹⁷ Vylor is roughly twice the first and far larger than the second. A rival can do equally good science, but each acre then carries more of the cost.

Price for value

The company calls its approach “price for value”. The seed has to earn the farmer more than it costs. The numbers it gives are: Pioneer Z-series soybeans beat all competitors by 3.5 bushels an acre on average in the 2024 comparison it cites, and a leading corn hybrid gave more than $300 of value per bag against a $100 price rise over ten years.²³ If the farmer gets two thirds of the value, the farmer keeps buying. The test is whether this is a pricing model or a record, and the 3% price and mix in 2024, 2025 and the first half of 2026 says it is both.²

Ability to turn a cost into income

This is the new part. Royalties used to be a cost: about $700M net in 2020. By 2025 they were about $120M, and the company aims for a net income of $300M by 2030 and $1B by 2035.³ In the first half of 2026 cost of goods fell $85M against the prior year, $50M of it from lower royalties, and management says that lower royalty expense has driven the improvement so far, and that from here it expects out-licensing income to drive it.² Two things stand behind the claim: freedom to operate in corn after the Bayer settlement, and a triple-stack corn trait platform open for licensing from 2027.³ Against it: the Enlist patents expire in 2031 and 2032, and Bayer’s new soybean stack arrives in 2027.²⁵ Management calls licensing its main short-term value driver. The record so far is $317M of gross income in 2025 against $439M of royalty cost.²³

A read on the customer

Direct agents see orders and plantings before the season, and that feeds product and inventory plans. Customers prepay: deferred revenue was $3.2B at the end of 2025, then fell to $0.3B at mid-year as seed shipped.² That is cash from the buyer before the seed is delivered. It also means a bad season shows up in the first half of the year, all at once.

The disadvantage

The model works from a base of 80% of sales in the Americas and 71% in corn. Brazil adds credit risk: management lists higher bad debt in Brazil in 2025 and again in the first half of 2026, and it guarantees some customer loans.² And the advantage that came from being part of Corteva is gone. The company gives no estimate of what it will cost to stand alone. It does say that it expects to take out corporate costs: $58M in 2025 terms, shown as a pro forma management adjustment.² The savings come from people and outside help it will not backfill. What it does not say is what the new systems, public-company costs and lost purchasing scale will cost. I can’t know until a year or two of results exist.

IVManagement

I follow the money in this section: how the people running Vylor are paid, what that pays them to do, how much of their own money is in, and what they did with capital before.

Who runs it

Charles Magro, 56, is the chief executive. He ran Corteva from November 2021 and before that ran Nutrien and Agrium, the fertilizer companies, where he did a number of acquisitions.² David Johnson, 59, is chief financial officer; he joined Corteva in September 2024 after six years as CFO of Atkore.² The chief technology officer, Sam Eathington, 57, came from Bayer’s Climate Corporation; the chief commercial officer, Judd O’Connor, 55, ran Corteva’s North American business.² The team has about 95 years of industry experience between them and almost all came from Corteva.² That is continuity, which I count as a plus, and it also means the same people who managed the costs and the allocation of costs between seed and crop protection now run the standalone company. The board has seven members, six independent. The chair is Karen Grimes, a former Wellington Management portfolio manager, and the board includes former executives of Monsanto, Deere, Procter & Gamble, Merck and Ultrapar.²

How they are paid

Vylor’s own pay plan is not out yet. The Form 10 sets out Corteva’s, which the Vylor team has been paid under, and the board has adopted a 2026 omnibus plan.²¹⁸ In 2025 Magro’s total pay was $17.5M: $1.4M salary, $9.3M in stock units, $2.3M in options and $4.0M in annual bonus.² About 91% of his target pay is at risk. Of the part at risk, 15% is tied to annual goals and 85% to financial goals or share price over several years. Payouts are capped at 200% of target.²

What does it reward? For 2026 the bonus is based on operating EBITDA (75%) and operating EBITDA margin (25%). The committee dropped the free-cash-flow measure for 2026, saying that goals were hard to set with capital decisions pending around the spin, and that it expects a cash measure to matter for Vylor later. Long-term awards were changed in 2026 to half performance units and half time-vesting units, and options were dropped.² The 2025 performance units paid on return on net assets and cumulative operating earnings per share.² One thing here bothers me. Operating EBITDA ignores amortization, currency losses, restructuring, separation costs and “significant items”, and it ignores the capital a business uses. The $610M Bayer settlement is a significant item and does not touch the bonus measure. A plan that pays on EBITDA and margin pays for growth in profit before the cost of cash, and it is silent on how much cash an owner gets to keep. The return-on-assets measure in the long-term plan partly covers that. I will see what the board adopts for Vylor itself.

Their own money

Magro’s Form 4 of 5 October reports 834,809 Vylor shares, worth about $59M at $71.25, and the finance chief reports 166,357, about $12M.⁶ Those came as the spin-off dividend of one share for each Corteva share held, and the form does not split out how many are unvested stock units, so I can’t say how much is purchased stock.⁶ The Corteva policy asked the chief executive to keep shares worth six times salary, about $8.4M, and Vylor says it will adopt similar rules.² Since trading began no insider has bought or sold in the open market. The three Forms 4 filed on 26 October are grants of 2,610 shares each to new directors.⁷

What they did with capital before

Over the cycle I can see, the record at Corteva as a whole is steady. Weighted shares fell from 709M in 2023 to 680M in 2025 and 667M at the spin, a 6% fall in three years, and Corteva returned about $1.5B to holders in 2025 and $740M in the first half of 2026 through buybacks and dividends. These figures cover seed and crop protection together, so they say little about Vylor alone.² The company’s own choices on seed were these. It paid $610M to end the Bayer dispute rather than risk it, and it now says it has freedom to operate in corn.²³ It acquired two biologicals firms in March 2023, which went with crop protection.² And it chose a capital structure for the spin in which Vylor borrowed about $3.5B and passed the cash to New Corteva.² That fits the legal form, and it also puts the debt on the company whose stock I am valuing.

The plan for the next three years is to generate $7B to $8B of operating cash flow and $5.5B to $6.5B of free cash flow in 2027 to 2029, and to use about 20% for capital spending, 15% for dividends and 65% for acquisitions and buybacks.³ Dividends are meant to be about 15% of operating cash flow.² M&A is the part I watch. Management says its targets are wheat, adjacent crops and gene editing, with discipline on price and a hurdle rate, and that it expects “small” deals.³ Companies of this size often say the same thing before a large one. Two limits apply. The tax rules for a tax-free spin restrict share issuance and some repurchases, and the 13 October filing says the company told the court it would not declare dividends or repurchase shares while the Seventh Circuit considered a stay.²⁸ The company has announced both since. On 22 October the board approved a multi-year repurchase program of up to $3B, effective at once, with no expiry and no start date, and declared a quarterly dividend of $0.13 a share for holders of record on 30 November, payable on 7 December.²⁵²⁶¹¹ That dividend is $0.52 a year, about $350M on 667M shares and a 0.7% yield at $71.25 C (calculated). The $3B is 6.3% of today’s market value C (calculated), and at this price each dollar spent on buybacks buys 3.6 cents a year of 2026 owner cash, against 4.9 cents from a ten-year Treasury C (calculated). I read both releases as republished by Placera, because the company’s news pages would not load for me, and I found no Form 8-K about either. They came nine days after the 13 October filing said the company did not intend to declare dividends or repurchase shares while the stay motion was pending, and I could not find out whether the Seventh Circuit has ruled since. So I treat the $3B as an authorization and not as shares bought, and my values do not depend on it.

Who is on the register

Because the shares went to Corteva holders, the owners are the usual index funds and long-only managers. The Form 10 expected BlackRock at 7.6%, Vanguard at 7.6%, Capital World at 6.6%, State Street at 5.2% and FMR at 5.2%, based on their filings on Corteva.² Those are stakes in Corteva as of dates between late 2023 and mid-2026, not confirmed Vylor holdings. No 13F can show a Vylor position before the quarter ending 31 December, which is due in mid-February.

VFinancials

I can show eight years for sales and segment EBITDA, because Corteva’s Seed segment is public back to 2018, and three audited years plus a half-year for the carve-out. I can’t show ten years because Vylor, as a company, has not existed that long. Each table says which basis it is on.

Over those eight years sales grew from $7.8B to $9.9B, 3.4% a year C (calculated). Sales dipped in 2019 and climbed in 2021 and 2022. Segment operating EBITDA more than doubled in six years, from $1.0B in 2019 to $2.6B in 2025, and I treated the 2018 and 2019 figures with care because Corteva labelled them pro forma.¹³¹⁰ The carve-out figures are lower, $2.4B for 2025, because the carve-out takes in costs that the segment measure leaves out.

The three-year carve-out

Three features stand out. Cost of goods has fallen from 54% of sales to 48% in two years. In 2025 the drivers were $190M of lower commodity costs, $125M of productivity and $50M of lower royalties, and the first of those can reverse. Amortization of acquired intangibles, $489M in 2025 and $276M in the first half of 2026, which includes a faster write-off of retired trade names, is an accounting cost and not a cash one; much of it comes from the old DowDuPont merger and is slowly running off. And the tax rate runs 30% to 32% on the carve-out basis against 26.5% in the first half of 2026, which reflects foreign tax credits, repatriation taxes and valuation allowances in Brazil and Argentina.²

The seasonality matters for two reasons. First, any quarter before March tells me very little. The third quarter, due on 11 November, falls in the second half, which lost money before interest in 2025.¹¹² Second, it makes the balance sheet swing. Customers prepay, so deferred revenue was $3.2B at the end of 2025, then fell to $0.3B by mid-2026. Receivables rise to $3.9B by June and inventory falls. Operating cash flow was −$2.5B in the first half of 2026 and the company expects it to come back in the fourth quarter.²³ Finance chief David Johnson told analysts that the third quarter is the high point of net debt, and that the fourth brings in several billion dollars of cash.³

What an owner can take out

Two items in this bridge need saying out loud. Stock pay is only $43M, small next to $2.4B of EBITDA, so dilution is not a concern at this size. And exchange losses of $97M, $114M and $120M in the last three years, and $132M in the first half of 2026, are excluded from operating EBITDA although they have been there every year.² A business with Brazil, Argentina and Turkey in it will have them. I count about $100M a year in my cash flows as a real cost. Cash taxes paid were $235M in 2025, about 10% of operating EBITDA. I assume more, 26% of earnings before tax, because the low cash figure reflects timing and the Bayer deduction and I don’t think it lasts.

Three versions of the same year

The balance sheet

The carve-out had almost no debt, $112M at the end of 2025. Vylor starts with a different balance sheet.² On 1 October it had about $5.7B of borrowings against $1.1B of cash and a $3.0B five-year revolver, a $1.5B 364-day revolver and a $3.5B commercial paper programme.²¹⁸ The notes carry coupons from 2.30% to 5.625%, and the pro forma average cost is about 4.7%.²¹⁹ At that rate, $5.7B costs about $265M a year at the peak. The pro forma interest charge was $175M in 2025 and $68M in the first half of 2026. I do not know the average balance the company will carry over a year, which is why interest is not in my owner cash and I deduct net debt instead.

Equity was $12.3B on a pro forma basis at 30 June, against a market value of $47.5B; goodwill and intangibles together are $12.3B C (calculated).² Property, plant and equipment is $2.4B net. This is an asset-light business whose book value says almost nothing about what it earns.

The price record is short. Closes ranged from $67.26 to $76.94, and the 52-week range, which is all of its life, is $65.00 to $77.39 intraday.¹²⁰ The volume on the first two days was 15.0M and 13.6M shares, then 2M to 5M on most days.²⁰

VIValuation

First, how this goes badly wrong

Before the numbers, I asked what would most likely ruin this business or this investment, and worked back from that. Three things could, and none needs a surprise.

• The licensing story doesn’t arrive. The case for higher margins rests on Vylor turning a $122M net royalty cost into $300M of net income by 2030 and $1B by 2035.³ The patents on its Enlist traits expire in 2031 and 2032. Bayer plans a five-herbicide soybean stack for 2027 and says it will regain trait leadership in North America by 2032.²⁵ If rivals match the traits and farmers move, Vylor goes back to being a very good seed seller with a flat royalty line. Margin stays near 26%, and that is my bear case.
• The debt meets a bad year. Vylor starts with about $5.7B of borrowings at the seasonal peak and a plan to spend about 65% of its free cash on acquisitions and buybacks.²³ A cold, wet spring, a crash in corn prices or a run of unpaid Brazilian bills would hit the first half of the year, when the profit is made and the cash is out. The company aims for investment-grade ratings, and I haven’t found a published rating yet.² Buying back stock while carrying seasonal borrowings leaves less room if the spring goes wrong.
• A court puts a claim on the assets. Fifteen states and one other government say the separation moved Corteva’s best assets away from creditors of the former DuPont entities, who may be owed large PFAS liabilities.⁸⁹ The Form 10 says legacy PFAS liabilities stay with New Corteva, unless they are primarily seed-related, and a federal court declined to enjoin the spin in September.²²¹ I cannot judge how this ends. Each $1B that landed on Vylor would cost about $1.50 a share C (calculated), and I put none of it in my numbers.

All three come to one question: is this a high-quality compounder whose margin keeps rising, or a very good seed business at a cyclical high with a new debt load? My bear case is the second.

What the price implies

At $71.25 the market values Vylor at $47.6B on 668M diluted shares, the 667.2M the Form 10 expects plus 1.2M of dilution at the pro forma rate C (calculated).²¹ The enterprise value, adding the net debt I expect at year end, is $49.6B, or 17.7 times pro forma operating EBITDA of $2.8B for 2026. At October’s net debt the multiple is 18.6 times. The owner cash I expect for 2026, $1.7B, is a 3.6% yield, against 4.90% on the ten-year Treasury E (estimate).³²² The company itself describes its plan as high single-digit growth, margins near 30% and at least 60% cash conversion, and calls Vylor a “classic growth compounding company”.³

What does the price pay for? On my bull margins, which reach 36%, the price needs sales to grow 7.7% a year for ten years, about double the plan’s 3% to 4%. On my base margins it needs 10.3% a year. Or, with my bull growth, it needs a 2036 margin of 48%. Put another way, my base case is worth the price at a discount rate of 6.9% and my bull at 8.0%. Over the 4.90% Treasury those rates are premiums of 2.0 and 3.1 points, against the 4.41% Damodaran measures for the whole market C (calculated).²²²³ The market is paying for something beyond management’s plan, or it is using a much lower rate than I do.

What I can’t judge

Five inputs matter and I can’t know them yet. I show the range, not a precise number.

• Standalone costs. The Form 10 says it is not practicable to estimate them, and the pro forma statements show only savings, $58M a year.² I allow zero in the bull case, $70M in the base and $150M in the bear. Each extra $100M a year takes about $1.38 off a share C (calculated).
• The final debt. The $5.7B is a 1 October estimate for a seasonal peak. The company points to 0.8 to 1.1 times EBITDA at year end, which implies $2.2B to $3.1B of debt. I use net debt of $2.0B: debt at the midpoint, about $2.65B, less about $0.65B of cash. Cash was $1.1B at the October low, so year-end net debt could well be lower, and each $1B lower adds about $1.50 a share C (calculated). At the October level my base would be about $37 instead of $41.
• Dis-synergies. Seed treatments and some patent rights come from New Corteva, and transition services last up to 24 months.² The price and the term after that are not known.
• The first results. On 11 November the company reports the third quarter, in a half of the year that loses money. The first full year as a public company will not be known until early 2027.¹¹
• The court. I can’t put a number on it, so I show the cost per $1B and leave it out.

The discount rate

I use 9.5%. The ten-year Treasury yielded 4.90% on 4 November, and Damodaran’s implied equity risk premium was 4.41% on 1 November.²²²³ With a beta of 1.0 that gives 9.3%. Damodaran’s page measures that premium against a 5.29% risk-free rate, which would give 9.7% on his basis.²³ Vylor has traded for 25 sessions, so it has no beta of its own; Corteva’s history blends seed and crop protection and is split by the spin, so I won’t borrow it. I took a beta of 1.0, for a business that is steadier than the market in food demand and less steady in weather, currency and farm income, and settled on 9.5%, between the two figures, as a small allowance for having no record.

Three cases

The model is simple on purpose. For each year from 2027 to 2036 I set sales growth and operating EBITDA margin. I take off exchange losses and standalone costs, which are real, then cash taxes at 26% of earnings before tax and after depreciation and amortization of $0.8B, then capital spending at 3.8% of sales and 10% of added sales for working capital. Stock pay is already in the EBITDA. What is left is owner cash before interest, and I take net debt off the enterprise value. It lands near the company’s 60% conversion target: my base is 62% of EBITDA in 2027 and 63% in 2036 C (calculated).

My base is lower than management’s plan on purpose. The plan calls for 2029 EBITDA of $3.3B to $3.7B and my base has $3.27B, about 7% under the midpoint. Why? The target is seven weeks old, from a company that has not reported as itself, and the CFO said the framework offsets $200M of productivity with $200M of cost inflation, which leaves little slack.³ The plan’s own margin gain, from 27% to 30%, needs the licensing line to move. My bull case is the plan, hit in full and carried on to a $1B net licensing position by 2035. So the bull is what management’s plan is worth at my rate.

The plan at a lower rate is a different answer. If I used 7.5%, close to what a market that values scarce, low-capital assets might use, my bear would be $46, my base $61 and my bull $80, and the price would sit between the base and the bull E (estimate). That shows where the argument is. Not the cash flows, which are close to management’s: the three-year owner cash I get is $5.8B in my base and $6.4B in my bull, against the company’s $5.5B to $6.5B of free cash flow C (calculated).³ It is what rate to put on them and how long they grow.

The price sits 74% above my base, and that is the plain result. Why might the market be right? Several reasons. I know of no other large listed pure-play seed and trait company, so there is scarcity value. The licensing line is a business that could be worth more than a copy of my cash flows: if a technology owner can charge for every acre without carrying inventory, the margin could rise past 36%. Gene editing and hybrid wheat, which I put at nothing beyond what is in the plan, could add. And 25 sessions of a new listing say little about what holders think it is worth. If the market is right, then my discount rate is too high or my growth too low, and the table above shows what that costs. Against that, the price is above my bull case by 34%, a gap like the 38% on my Costco page and the 40% on my Walmart page, and well above the 5% on Monster Beverage’s.

Other uses of the same dollar

The ten-year Treasury pays 4.90%. My base here returns 2.8% a year at $71.25 and my bull 5.9% E (estimate).²² That is less than the Treasury in the base case. The closest comparisons on this site are other well-run companies with prices above my base. Costco returns 6.2% on its page’s base case, Walmart 5.5% and Monster Beverage 7.0%. Those pages use their own rates and methods, so I treat a gap of a point as noise. Vylor’s base is lower than all three, and its bull of 5.9% is lower than Monster’s base. In the same way Visa, a steadier business, has a price 18% above its base. So for the same dollar I would put Vylor, on my numbers, among the more fully priced businesses on this site, not among the cheaper ones.

The margin of safety

• Price$71.25Close, Q4 2026 [1]
• Base value$41My estimate E (estimate)
• Margin of safety below$3320% under base C (calculated)

I set the margin of safety at 20% under my base value, $33. That is a rule of my own for this page, and the reason is that the usual one, where my bear is at least three quarters of the price, would give $41, which is my base. The bear and base are close together here, because the cash flows are steady and the real unknowns, the court, the final debt and licensing, sit outside the range. At $33 my bear value of $31 is 94% of the price, and my bear returns 8.6% a year, my base 12.5% E (estimate). The stock has not closed below $67.26 in its 25 sessions. The price is 116% above $33, so there is no margin of safety on my numbers. The stress case does not help either: sales flat, margin falling to 22% and $150M each of standalone costs and exchange losses gives $23.

Two different questions

How good is the business, and how good is the price? They are separate. As a business Vylor looks very good on most tests I have: a leading brand, large research spending, rising margins, low capital needs and cash that is close to earnings once the one-offs are out. Its flaws are the ones in this section: a short record as itself, a debt load it didn’t have, a lawsuit that could still matter, and a licensing plan that is large and unproven. The price is another matter. At $71.25 it needs more than management itself plans, on my numbers, and returns less than the ten-year Treasury pays. So this reads as a good business at a high price with open questions, which is different from a good business at a bad price. I can’t prove the first half, because the record is three carve-out years, and the second half depends only on arithmetic you can check.

VIIThe case for the price

What most people miss

Three things cut in Vylor’s favour and get little attention. The royalty line has already moved a long way: from a net cost of about $700M in 2020 to about $120M in 2025, a $580M improvement, equal to a quarter of 2025’s operating EBITDA, before any of the licensing growth that is planned C (calculated).³² Second, customers fund the winter. They prepaid $3.2B by the end of 2025, and by June most of it had turned into delivered seed and receivables.² Third, the legal position in corn changed in February 2026, when management says Vylor gained freedom to operate after the Bayer settlement, and from 2027 it can open a triple-stack corn trait platform to licensees.³

The bull case

In plain words: Vylor owns what its bulls call the best corn and soybean genetics in North America, pays much less in royalties each year, and is about to be paid by other seed firms for what it invented. Management’s version is from the Investor Day on 15 September 2026. Chuck Magro described high single-digit growth, margins near 30%, and at least 60% of earnings converting to cash, and called it a “classic growth compounding company”. Management put 2029 operating EBITDA at $3.3B to $3.7B, a 7% to 8% annual rise from about $2.8B. It said the plan assumes steady acreage, commodity prices, demand and trade policy, and that it does not depend on regulatory approvals.³

Outside, a data site lists ten banks that began coverage in October, nine with price targets from $75 to $89: UBS $89 on 12 October, Goldman Sachs $87 on 8 October, RBC, Morgan Stanley and BMO $85 on 2 October, down to BNP Paribas at $75 on 14 October. Every target is above the $71.25 close.²⁴ I could not read their notes and the source is a data site, so these are secondhand and I can’t say what they assume. I expect they lean on the Investor Day framework, but I can’t see their models. No fund position can be shown yet, since the first 13F filings showing Vylor shares are due in February 2027.

Against reality

If Vylor does what it says it will do, the price is possible only at a lower rate than mine. My bull case is the plan: sales up 4% to 2029, EBITDA of $3.54B in 2029, net licensing of about $1B by 2035. At my 9.5% it is worth $53. At 7.5% it is worth $80, above the price. So the price is the plan, delivered, valued at a low rate. Today’s numbers are on the way: operating EBITDA grew 9% in the first half of 2026, price and mix has run at 3% for three straight periods, and cost of goods fell from 54% to 48% of sales C (calculated).² But the plan needs the next three years to look like the last two on margin, and the last two had falling commodity costs.

It helps to multiply it out. My bull needs four things. The plan is met through 2029: 60%. Net licensing reaches about $300M by 2030: 55%. It reaches $1B by 2035, through the patent expiries: 35%. No adverse legal ruling: 80%. Those are my guesses. Multiplied, they give about 9% E (estimate). They overlap, so perhaps 15% in practice. The price needs more than that. It needs a rate near 8% as well, or 7.7% growth for ten years at my margins, about double what the company plans.

What a 10x would take. Ten times $71.25 is $712.50, or about $475B of market value on today’s shares. At today’s multiple of 17.7 times pro forma EBITDA, that needs about $27B of operating EBITDA, nearly 10 times 2026 C (calculated). At a 36% margin, the highest I model, that is about $75B of sales, 7 times the $10.4B of 2026. By 2036 it needs 22% growth a year for ten years. From 2018 to 2025 the Seed segment grew 3.4% a year, and Syngenta’s whole seeds unit sells $4.8B.¹⁰¹³¹⁶ I know of no seed or farm-input company that has done anything like it from this size. For Vylor a tenfold rise is close to impossible, and I would not build a case on it.

Where I come down

What moved me: the royalty line has already improved by $580M in five years, and margin has nearly doubled in six, which makes the plan more credible than the usual spin-off promise. What didn’t: the price, which needs more than the plan, and a court case I can’t size. What would raise my values: a net licensing position above zero in 2026, gross licensing income above $500M in 2027, free cash flow of at least 60% of EBITDA in the fourth quarter of 2026, and a ruling that leaves the separation as it stands.

VIIIRisks, and what would change my view

The three ways this goes badly wrong are at the start of Valuation: licensing that stalls, debt that meets a bad year, and the court. These are the rest.

• Weather and farm income. Planted area, commodity prices and weather drive demand. In the first half of 2026 volume was flat as higher soybean area was offset by lower corn volume in the US, Europe and Brazil.² Nearly all the profit is made in the first half, so a delayed spring hurts the year.²
• Concentration. Corn is 71% of sales and the Americas 80%.¹⁰²
• Currency and credit. Exchange losses of $97M to $132M a year, rising bad debt in Brazil and customer-credit guarantees.²
• Dependence on New Corteva. Exclusive purchases of seed treatments, patent licences inside Vylor’s fields, and 24 months of services.² Either side can end the supply agreement for an uncured breach, or if the other changes hands.
• Tax-free spin rules. The company agreed to limits on share issuance and certain repurchases and on deals that change its ownership, to protect the tax-free treatment, and has to indemnify New Corteva if it breaks them.² That narrows the buyback and M&A plan.
• Regulation of gene editing. The company's gene-edited products depend on regulators, and the multi-disease corn is targeted for a 2028 US launch.² A global rollout is subject to regulatory developments.²
• Environmental. The AltEn ethanol site in Nebraska, where Vylor is one of six seed customers contributing to clean-up, and a February 2026 reservoir overflow at the AZ Concordia site in Chile, which the filing describes as Corteva’s. I can’t tell which company ends up with it.²
• Pay and incentives. A bonus based on EBITDA and margin, not cash, as I describe above.²